Key Points
- Major shareholder Plc Gsk purchased 1,470,000 shares of GSK on December 11 at an average price of $19.00 per share (~$27.93M), increasing its direct holding to 18,245,691 shares — an 8.76% ownership increase disclosed in an SEC filing.
- GSK recently beat quarterly expectations with $1.48 EPS and $11.35B revenue, set FY2025 guidance of 4.73–4.81 EPS, trades with a market cap of about $100.5B and a ~3.4% yield, and carries mixed analyst ratings with an average target of $44.13.
GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) major shareholder Plc Gsk bought 1,470,000 shares of GSK stock in a transaction on Thursday, December 11th. The shares were purchased at an average cost of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the purchase, the insider directly owned 18,245,691 shares in the company, valued at $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
GSK Price Performance
Shares of NYSE:GSK opened at $49.25 on Tuesday. The firm's 50 day moving average is $46.39 and its two-hundred day moving average is $41.92. The firm has a market capitalization of $100.45 billion, a P/E ratio of 13.91, a PEG ratio of 1.32 and a beta of 0.45. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $49.39.
GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The business had revenue of $11.35 billion during the quarter, compared to analyst estimates of $8.21 billion. During the same period in the prior year, the company posted $0.50 EPS. The business's revenue for the quarter was up 6.7% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. Analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.
GSK Cuts Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 8th. Stockholders of record on Friday, November 14th will be issued a dividend of $0.4171 per share. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend is Friday, November 14th. GSK's dividend payout ratio (DPR) is 46.33%.
Institutional Trading of GSK
A number of large investors have recently added to or reduced their stakes in the business. TOWER TRUST & INVESTMENT Co grew its position in GSK by 1.3% in the third quarter. TOWER TRUST & INVESTMENT Co now owns 23,195 shares of the pharmaceutical company's stock worth $1,001,000 after buying an additional 293 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of GSK by 2.1% during the 1st quarter. Rhumbline Advisers now owns 18,403 shares of the pharmaceutical company's stock worth $713,000 after acquiring an additional 386 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of GSK by 3.1% during the 2nd quarter. Valeo Financial Advisors LLC now owns 12,989 shares of the pharmaceutical company's stock worth $499,000 after acquiring an additional 388 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of GSK by 16.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,854 shares of the pharmaceutical company's stock worth $123,000 after acquiring an additional 393 shares during the last quarter. Finally, Fiduciary Alliance LLC lifted its holdings in shares of GSK by 3.6% during the second quarter. Fiduciary Alliance LLC now owns 11,846 shares of the pharmaceutical company's stock valued at $455,000 after purchasing an additional 407 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several research firms recently weighed in on GSK. HSBC reaffirmed a "reduce" rating on shares of GSK in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of GSK in a research note on Monday, December 8th. Bank of America upgraded shares of GSK from an "underperform" rating to a "neutral" rating in a research note on Tuesday, November 25th. Cfra set a $53.00 target price on GSK in a report on Thursday, October 30th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of GSK in a research note on Monday, October 27th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $44.13.
Read Our Latest Research Report on GSK
About GSK
(
Get Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
